Abstract
Microglia are brain-resident immune cells with a repertoire of functions in the brain. However, the extent of their interactions with the vasculature and potential regulation of vascular physiology has been insufficiently explored. Here, we document interactions between ramified CX3CR1 + myeloid cell somata and brain capillaries. We confirm that these cells are bona fide microglia by molecular, morphological and ultrastructural approaches. Then, we give a detailed spatio-temporal characterization of these capillary-associated microglia (CAMs) comparing them with parenchymal microglia (PCMs) in their morphological activities including during microglial depletion and repopulation. Molecularly, we identify P2RY12 receptors as a regulator of CAM interactions under the control of released purines from pannexin 1 (PANX1) channels. Furthermore, microglial elimination triggered capillary dilation, blood flow increase, and impaired vasodilation that were recapitulated in P2RY12−/− and PANX1−/− mice suggesting purines released through PANX1 channels play important roles in activating microglial P2RY12 receptors to regulate neurovascular structure and function.
Subject terms: Microglia, Molecular neuroscience, Neuro-vascular interactions
Microglia are involved in debris clearance and synaptic pruning, among other processes. However, their direct interaction with the brain vasculature is less clear. Here, the authors show that capillary-associated microglia (CAMs) regulate vascular tone via PANX1-P2RY12 signalling.
Introduction
The brain is an energy-demanding organ1–3 and its energy demands are met by a rich and dense supply of blood vessels4. While peripheral organs allow less restricted entry and exit of substances in the blood circulation, the brain’s vasculature is protected structurally by components of the blood–brain barrier (BBB) that allow very restricted entry of blood contents into the brain5–7. The brain vasculature is also different from the vasculature of other organs as it consists of the neurovascular unit (NVU), which is made up of various cell types consisting of vascular (i.e., endothelial cells, pericytes, smooth muscle cells, and perivascular macrophages (PVMs)) and brain (i.e., astrocytes and neurons) cells8,9.
Microglia are the brain’s immune cells10–12 that play important roles in development, mature homeostasis, and disease12–14. During development, microglia are known to facilitate optimal vascular complexity development15–17 and regulate vascular development in various pathologies18. For example, microglial elimination in Alzheimer’s disease increases vascular hemorrhage and amyloid beta deposition on blood vessels reminiscent of cerebral amyloid angiopathy19, suggesting protective roles for the vasculature by microglia. In addition, microglia react to systemic inflammation with increased vascular interactions20 and play a dual role in regulating BBB integrity following an inflammatory insult21. Finally, in response to acute vascular injury, microglial processes extend to “plug the leak” and restore vascular integrity22. However, the degree to which they interact with the vasculature in homeostasis has not been adequately studied23,24. Because the vascular system is essential for the delivery of oxygen and nutrients to (as well as the elimination of waste from) the brain, an understanding of microglial interactions with the vasculature is vital to our understanding of brain homeostasis.
In the current study, using acute and longitudinal in vivo two-photon imaging we identified ramified myeloid cells that stably interact with brain capillaries with their cell bodies. Molecular, morphological, and electron microscopic analyses identified these cells as bona fide microglia that are resident in the brain proper rather than PVMs that reside in the perivascular space. Characterization of capillary-associated microglia (CAMs) revealed (i) that they are enriched on the vasculature (about a third of the microglial population) than is expected at random based of the brain blood vessel density; (ii) that while microglial processes are known to make transient physical contacts with the neurovasculature, these CAM interactions occur through the more stable microglial somata; (iii) that they exhibit mostly similar features with parenchymal microglia (PCMs), suggesting that they are unlikely to be ontogenically or functionally distinct cells; and (iv) that their interactions with capillaries are at least in part regulated by purinergic P2RY12 signaling activated by purines released from pannexin 1 (PANX1) channels. Finally, pharmacological treatment to eliminate microglia resulted in an increase in capillary diameter, cerebral blood flow (CBF), and impairment in vasodilative responses, which were recapitulated with P2RY12 and PANX1 deficiencies. Together, these results provide evidence into the identification, characterization, interaction mechanisms, and functional significance of CAMs, highlighting microglia as bona fide components of the NVU.
Results
Ramified CX3CR1+ myeloid cells associate with brain capillaries
To begin to study brain-resident myeloid cell interactions with the neurovasculature, we performed in vivo two-photon imaging on CX3CR1GFP/+ mice. We observed CX3CR1+ cells that had their cell bodies attached to the vasculature. These vessel-associated CX3CR1+ cells were present on blood vessels of all sizes and through the depth of the cortex analyzed (Fig. 1a–d and Supplementary Video 1). We focused on capillaries (ranging from ~5 to 10 µm in diameter) because the capillary bed represents the most elaborate component of the vasculature, the site of oxygen/nutrient delivery and waste uptake, and often undergo the most elaborate remodeling. Capillaries exhibited closely attached ramified GFP+ cell bodies (Fig. 1e). Close examination revealed that these cells were in the same focal plane as the adjacent capillary and their ramifications extended into the brain proper, suggesting that they are brain-resident (Fig. 1f–h).
Astrocytes are well known to interact with the vasculature as a component of the NVU25. To compare the density of these capillary-associated myeloid cell bodies to the cell bodies of astrocytes, we examined capillary-associated astrocyte cell bodies in 1-month-old ALDH1L1GFP/+ mice26. Capillary-associated myeloid cell body density was significantly greater than capillary-associated astrocyte cell body density on capillaries in the cortex in vivo (Fig. 1i–j). However, capillary-associated myeloid cell body density was much lower than capillary-associated pericyte (which reside in the perivascular space) cell body density27. Taken together, these findings indicate that ramified CX3CR1+ myeloid cell bodies associate with brain capillaries.
Ramified CX3CR1 + capillary-associated myeloid cells are bona fide microglia
Brain myeloid cells include ramified microglia, PVMs, meningeal macrophages, and choroid plexus macrophages28. These cortical capillary-associated GFP+ cells were ruled out to be meningeal or choroid plexus macrophages. However, PVMs are localized between the two vascular basement membranes, and microglia are localized outside the basement membrane of the vascular wall in the brain parenchyma. Electron microscopy identified myeloid cells associated with capillaries in the brain parenchyma (outside the basement membranes) in different brain regions (Fig. 2a) consistent with the previous reports21,23,24,29. Furthermore, we noted that the cell bodies of these myeloid cells were directly adjacent to the corresponding vessel and contacted the basement membrane without intervening astrocytic processes as has recently been reported elsewhere24.
CX3CR1GFP/+ tissues stained with CD206- (a PVM marker28) labeled cells in the meninges and cortical parenchyma (Supplementary Fig. 1a–d and Table 1). Remarkably, we observed that most GFP+ cells were CD206-negative (CD206−) and most CD206-positive (CD206+) cells in the brain were localized to large blood vessels and the meninges (Fig. 2b, d and Supplementary Fig. 1a–d). Of all labeled cells, 90.8 ± 1.45% were GFP+ only, 6.03 ± 1.45% were CD206+ only, and 3.19 ± 0.04% were double positive for GFP and CD206. CX3CR1GFP/+ tissues were then stained with P2YR12 (a microglial-specific marker28,30–32). Occasionally, GFP+;P2RY12− cells could be detected in larger blood vessels (arrowheads in Supplementary Fig. 1e–h and Supplementary Fig. 2a–e and Table 1). Typically, these cells lacked ramified processes (unlike P2RY12+ cells) and sometimes expressed lower GFP levels (arrowhead in Supplementary Fig. 2a–c and right arrowhead in Supplementary Fig. 2d–e and Table 1). Virtually all non-meningeal GFP+ cells were P2RY12+ (97.16 ± 0.52%; Fig. 2c, e), and a population of the cell bodies of these cells was often localized to capillaries (arrows in Supplementary Fig. 3a–c). Therefore, we refer to these capillary-interacting, ramified CX3CR1+ (i.e., GFP+) cells as CAMs.
Table 1.
Quenching | Blocking | Primary | Secondary | |
---|---|---|---|---|
IBA1 | 2% H2O2 in 70% methanol for 10 min | 10% FCS + 3% BSA + 0.5% Triton, in Tris-buffered saline for 1 h at room temperature | 1:800 in blocking buffer O/N at 4 °C | 1:500 anti-rabbit antibody in Tris-buffered saline with 0.5% Triton |
CSF1R | 0.3% H2O2 for 10 min | 10% NGS + 0.2% Triton X-100 in PBS at room temperature for 1 h | 1:250 in blocking buffer O/N at 4 °C | 1:500 goat anti-rabbit in PBS + 0.2% Triton X-100 for 1.5 h at room temperature |
0.1% NaBH4 for 30 min | ||||
CD13 | – | 1% BSA + 2% Triton in phosphate-buffered saline for 1 h at room temperature | 0.8 μg/mL in blocking buffer O/N at 4 °C | 1:500 anti-goat in phosphate-buffered saline |
AQP4 | – | 10% NGS + 0.1% Triton in phosphate-buffered saline for 1 h at room temperature | 1:400 in blocking buffer O/N at 4 °C | 1:500 anti-rabbit in phosphate-buffered saline |
CD206 | 2% H2O2 in 70% methanol for 10 min | 10% FCS + 3% BSA + 0.05% Triton, in Tris-buffered saline for 1 h at room temperature | 1:300 in blocking buffer O/N at 4 °C | 1:500 anti-rat antibody in Tris-buffered saline with 0.05% Triton |
P2RY12 | – | 10% NGS + 0.4% Triton, in Tris-buffered saline for 1 h at room temperature | 1:400 in blocking buffer O/N at 4 °C | 1:500 anti-rabbit antibody in Tris-buffered saline |
CD31 | – | 5% BSA + 0.3% Triton in phosphate-buffered saline for 1 h at room temperature | 1:150 in blocking buffer O/N at 4 °C | 1:500 anti-Armenian hamster in phosphate-buffered saline with 0.3% Triton |
CAMs were present at similar densities in the cerebral cortex, thalamus, and hippocampus (Fig. 2f). Carefully generated 3D reconstructions of CX3CR1+ cell somata and the vasculature revealed physical interactions between the two brain elements (Fig. 2g and Supplementary Video 2). The vasculature occupied 6.1 ± 0.93% of the total brain volume, whereas ramified CAMs accounted for ~30% of the microglial population across brain regions (Fig. 2h). We reasoned that if 6% of the brain’s volume is occupied by blood vessels, then we could expect ~6% of microglial cell bodies to associate with the vasculature of the total microglial population if placed randomly in the brain. Our finding of ~30% of microglial cell bodies associating with capillaries in the brain, therefore, indicates that CAMs are 5× more enriched on the vasculature above what would be expected at random. Taken together, these results indicate that ramified CX3CR1+ myeloid cells are bona fide microglia.
Comparison between CAMs and PCMs
Based on their position along the capillary wall, at least three CAM categories were identified including lined CAMs whose somata are aligned parallel to the corresponding capillary; wrapped CAMs with bipolar processes that wrap around the capillary; and junctional CAMs whose somata reside at capillary bifurcations (Supplementary Fig. 4a). CAM density was maintained between P15 and 12 months at ~30% (Supplementary Fig. 4b), and they could be detected in the neonatal (P5) brain (Supplementary Fig. 4c and Supplementary Video 3). Male and female adult mice showed similar blood vessel volume and CAM density (Supplementary Fig. 4d). Interestingly, CAM density was increased with chronic window implantation when compared to an acute window preparation, suggesting that the window implantation approach slightly but significantly increases CAM interactions (Supplementary Fig. 4e).
CAMs are distinguished from PCMs by their position. Therefore, to further characterize CAMs, we compared the expression of Sall1, a unique microglial transcription factor among myeloid cells33 and noted no significant differences (Fig. 3a, b and Table 1). To interrogate possible static morphological and dynamic functional differences between CAMs and PCMs, we compared their static and dynamic morphological features. CAMs showed a slight but significant reduction in primary process numbers (Fig. 3c, d), a larger cell body area (Fig. 3e), but an identical cell territory (Fig. 3f). In response to a laser-induced injury, both CAMs and PCMs exhibited directed process extension (Fig. 3g–j and Supplementary Video 4). Longitudinal imaging of microglia daily or weekly (Fig. 3k), identified stable, crawling, “hop on” and “hop off” CAMs (Fig. 3l–o). When monitored over a month, stable CAMs were the most abundant CAM category (Fig. 3m, p). Together, these results suggest that CAMs represent an interchangeable microglial population with PCMs with extended cell body residence on capillaries.
P2RY12 and PANX1 channels regulate CAM interactions
A small population of microglia (~5–8%) in the cerebral cortex migrate daily under purinergic P2RY12 control34. Therefore, we investigated P2RY12 roles in CAM interactions and dynamics. First, we found no gross defects in vascular density in P2RY12−/− mice (6.1 ± 0.93% in wild-type and 5.5 ± 0.43% in P2RY12−/− mice; Fig. 4a). However, both male and female P2RY12−/− mice showed a significantly reduced CAM density (Fig. 4b–d). One allele of P2RY12 was sufficient to ensure normal CAM density (Fig. 4e). The reduction in CAM density was not a result of a reduced number of microglia in P2RY12−/− mice because these mice had a slight but significantly greater microglial density (Fig. 4f). The average spacing between CAMs along the vasculature was also greater in P2RY12−/− mice (387 ± 64 µm) compared to wild-type mice (223 ± 31 µm; Fig. 4g), although not statistically significant with the number of mice assessed, suggesting possibly poorer vascular surveillance in P2RY12−/− mice. Finally, monitoring CAM dynamics for a month revealed no statistical differences between stable and dynamic CAM subtypes in both genotypes (Fig. 4h), indicating that such dynamic interactions are not regulated by P2RY12.
Since P2RY12 is activated by purines35, which can be released from PANX1 channels36, we examined microglial density and CAM density in PANX1−/− mice and determined (as with a P2RY12 deficiency), that microglial density was significantly increased (Fig. 4i, j) and CAM interactions were significantly reduced in PANX1−/− mice (Fig. 4i, k). Together, these results indicate that P2RY12- and PANX1-dependent mechanisms regulate microglial density and CAM interactions.
CAM interactions are not altered by increased neuronal activity
Next, we asked whether CAMs are influenced by neuronal activity. To this end, we chronically implanted cranial windows and followed CAMs after kainic acid (KA)-induced seizures. We have previously shown that following severe seizures (i.e., stage 5 seizure scores along a modified Racine scale) induced by systemic KA treatment, microglia show increased cortical positional rearrangement of their landscape by translocation34. However, we did not assess the consequence of this approach to increase neuronal activity in vivo on CAMs. Therefore, we monitored CAMs daily before and up to 48 h after KA-induced seizures. Despite some changes in the microglial morphology from smaller somata to larger ones during this period, the total microglial density remained unchanged (Fig. 5b) as did the percent of the CAM population (Fig. 5c). Similarly, CAM dynamics following seizures (Fig. 5d) was identical to that in the basal condition (Fig. 3p). Moreover, this was the same when hippocampal microglial (Fig. 5e) and CAMs (Fig. 5f) density was assessed in fixed tissues following seizures, suggesting that CAM interactions and dynamics are not altered by increased neuronal activity. Importantly, KA treatment did not induce an increase in BBB permeability as assessed by Evan’s Blue extravasation (Supplementary Fig. 5).
Microglia regulate the vascular structure
To determine whether CAMs are an intrinsic or random subset of microglia, we eliminated and replenished microglia using PLX3397, a CSF1R inhibitor37. Notably, both CAMs and PCMs expressed similar levels of CSF1R (Supplementary Fig. 6 and Table 1), indicating that both microglial groups can be expected to be targeted by PLX3397. Treatment with PLX3397 effectively eliminated microglia (and does not affect BBB permeability37), while withdrawal of drug treatment resulted in its rapid repopulation (Fig. 6a, b). We observed in vivo what has been previously described in fixed brain slices37, i.e., that repopulating microglia show larger cells bodies and shorter processes (Fig. 6a). During PLX3397 treatment, total microglia and CAMs decreased and recovered after PLX3397 withdrawal. However, the CAM density of the residual microglial population remained constant (~30% of residual microglia) throughout the elimination–repopulation cycle (Fig. 6b), suggesting that CAM density in the microglial landscape is intrinsically regulated.
Microglial elimination during PLX3397 treatment preserved the overall vascular structure, i.e., no new vessels were formed, and no extant vessels were lost. However, while capillary diameter was maintained under controlled conditions (Fig. 6c–f, k), capillary diameter after 4 days of PLX3397 treatment increased by ~15% (Fig. 6g–k), suggesting that microglia contribute to the maintenance of capillary diameter.
Microglia regulate vascular function through PANX1–P2RY12 coupling
In addition, as a consequence of dilated capillaries, we measured CBF using laser-speckle imaging and detected a ~20% increase with PLX3397 treatment (Fig. 7a–d). Furthermore, with PLX3397 treatment, response to CO2 (a vasodilative agent) showed a trend towards impairment (Fig. 7e–f), suggesting that microglia regulate both blood flow dynamics and are necessary for at least some aspects of vascular reactivity. Given our observation that both P2RY12- and PANX1- deficient mice show reduced CAM interactions (Fig. 4), we hypothesized that this molecular mechanism may also regulate CBF and vasodilation. To test this hypothesis, we repeated laser-speckle imaging in age-matched wildtype, P2RY12−/− and PANX1−/− mice. Consistent with the PLX3397 findings, we observed increased basal perfusion levels as well as impaired vasodilation to CO2 with both a P2RY12 (Fig. 7g–i) and PANX1 deficiency (Fig. 7j–l). Because pericytes and astrocytes also regulate vascular function, we assessed pericyte cell density and astrocytic endfeet density in PLX3397-treated and P2RY12−/− mice. Neither the depletion of microglia nor a P2RY12 deficiency altered pericyte cell density or astrocytic endfeet density (Supplementary Fig. 7 and Table 1). Together, these results suggest that purines released from PANX1 facilitate microglial–capillary interactions, which function to regulate cerebrovascular perfusion and reactivity in the steady state.
Discussion
In this study, we have characterized the enrichment of microglia on capillaries and provided evidence for microglial involvement in the maintenance of capillary structure and regulation of CBF and vasodilation. Specifically, we show (i) that capillary-associated CX3CR1-expressing cells are bona fide microglia (or CAMs) using ultrastructural, morphological and molecular approaches; (ii) that CAM interactions are usually stably confined to capillaries but they sometimes can be interchanged with PCMs; (iii) that CAM interactions are regulated by a molecular mechanism that involves microglial-specific P2RY12 which are activated by purines released from PANX1 channels; (iv) that CAM density seems to be governed by a brain-intrinsic program to maintain a third of the microglial population on capillaries irrespective of the overall microglial pool; and (v) that microglia contribute to the maintenance of optimal capillary diameter, CBF and vascular responsiveness through the PANX1–P2RY12 coupling in the healthy state (Fig. 8). To our knowledge, this is the first report showing microglial contributions to capillary structure and function outside pathology. These findings have significant implications as a foundation to understand microglial contributions to vascular function that may be relevant especially in microvascular disease.
There has been growing interest in microglial diversity in the brain38,39, which has been revealed in recent years by transcriptional differences between microglia across and within species in health40,41 and following injury42,43. In addition to transcriptional differences, microglial diversity has been shown with regard to functional status. For example, with increased diversity in development, a subset of microglia have been identified as proliferation-associated microglia44. Furthermore, disease-associated microglia in neurodegeneration have recently been described45. In addition, “subsets” of microglia have been identified based on their location without known transcriptional differences. For example, axon initial segment (AXIS) microglia were discovered in relation to their position along the neuronal axon initial segment46 and vessel-associated microglia (VAMs) were recently described in relation to their position along blood vessels, although the identity of the blood vessels (capillaries, arterioles, veins, arteries) were not clarified21.
Others have previously47 and recently24 described “juxtavascular microglia” along blood vessels. In this context, “juxtavascular” referred to the association of the microglial cell body or process with the vasculature. “Juxtavascular” microglial cell bodies could be situated up to 50 µm from blood vessels, which varied in size from 4–30 µm47. This was examined in the neonatal (P4–10) rat hippocampus leaving open the question of microglia–vascular interactions in maturity. A more recent study using the same nomenclature identified juxtavascular microglia as increased in the early postnatal (P1-5) mouse and embryonic human brain that were reduced with maturity. This study showed that these interactions were predominantly directed to capillaries where CX3CR1 was shown to regulate their colonization of the brain. In maturity, these cells were stabilized at capillaries24, which we also found in the current study.
For our interests, we have focused our attention on microglial cell body interactions at microvascular capillaries (5–10 µm in diameter) because these are more stable than the highly dynamic microglial processes48,49. We confirmed the existence of microglial cell bodies associated with capillaries, which we call CAMs for precision. It is likely that CAMs are (at least a subset) of previously described VAMs21 or juxtavascular microglia24,47. We report that CAMs are highly enriched on capillaries at a rate that is 5× greater than would be expected at random. They make up about a third of the microglial population, a number that is similar to previous reports of VAMs or “juxtavascular microglia”21,24,47. Molecular approaches identified CAMs as expressing microglial-specific P2RY12 and similar levels of Sall1 transcripts and CSF1R protein to PCMs. Moreover, like PCMs that are not associated with capillaries, CAMs are ramified, respond chemotactically to a laser-induced injury, and can be depleted with CSF1R inhibition using PLX3397. Remarkably, even during PLX3397-induced microglial depletion or repopulation, CAMs maintain ~30% of the total microglial population, suggesting an intrinsic brain programming that ensures that a third of the microglial population remains on capillaries. Since microglial repopulation following PLX3397 treatment occurs solely from microglial proliferation without contributions from the periphery50, these findings suggest a brain-intrinsic programming of CAM interactions. The molecular basis for this intrinsic regulation remains unknown, but perhaps the vasculature could be a source of prosurvival microglial factors such as CSF1 and/or IL-34 known to regulate microglial survival and maintenance51.
Having clarified CAM identity, we set out to understand mechanisms regulating CAM interactions. Mechanisms regulating CAM interactions could be broadly classified into two types: (i) short-term attraction mechanisms and (ii) long-term attachment mechanisms. Given that microglia are well known to express purinergic receptors including P2RY12, which regulate microglial process35,52,53 and cell body movements34 and PANX1 channels present on the vasculature can release purines54–56, we tested the roles of P2RY12 and PANX1 in regulating CAM density. We consistently found a reduction of CAM density in respective knockout mice for these proteins suggesting a PANX1–P2RY12 regulating the attraction of microglia to capillaries. While this mechanism could serve as an attraction mechanism, purines are rapidly degraded in the extracellular space by enzymes and are unlikely to serve as a long-term attachment mechanism for CAM interactions, which could presumably be regulated by other yet-to-be-identified adhesion factors.
In addition to identifying CAMs and some of the molecular mechanisms regulating their interactions, using pharmacological and genetic approaches, we assessed the consequence of a loss of microglia and CAM-interaction mechanisms on capillary structure and function. Without altering pericyte or astrocytic endfeet density, microglial elimination with PLX3397 resulted in a ~15% increase in capillary size that corresponded with a ~20% increase in cerebrovascular perfusion, but an ~50% reduction in vascular reactivity to a vasodilative CO2 treatment. Some of these findings were recapitulated in P2RY12−/− and PANX1−/− mice, indicating an overlap in the molecular mechanism regulating CAM interactions, cerebrovascular perfusion, and vasodilative reactivity. It remains to be determined whether microglia elicit these effects on the vasculature directly or indirectly via the modulation of an intermediate cell type like astrocytes, pericytes, or neurons that are already known to regulate the vasculature. Moreover, whether microglia play significant roles in vascular reactivity other than CO2-mediated vasodilation remains to be investigated.
In summary, we have clarified the identity of CAMs, elucidated one underlying mechanism regulating these interactions in the PANX1–P2RY12 coupling and provided support that a feature of CAM interactions includes regulation of capillary structure and function. Together, these findings provide strong support for the inclusion of microglia as a significant component of the NVU as well as recommend further studies into microglial contributions to vascular structure and function.
Methods
Animals and treatment
Animal experiments were conducted in accordance with the relevant guidelines and regulations established and approved by the Institutional Animal Care and Use Committee at the University of Virginia. All animals were housed under controlled temperature, humidity, and light (12:12 h light–dark cycle) with food and water readily available ad libitum. Both male and female mice were used for this study. Heterozygous GFP reporter mice expressing GFP under control of the fractalkine receptor promoter (CX3CR1GFP/+)57 were used for the imaging studies as well as for immunohistochemical staining. For investigating the involvement of purinergic signaling, P2RY12−/−:CX3CR1GFP/+mice were generated by crossing P2RY12−/− mice58 donated by Dr. Long-Jun Wu at Mayo Clinic with homozygous (CX3CR1GFP/GFP) mice. The double heterozygote F1 generation was then subsequently re-crossed to generate P2RY12−/−:CX3CR1GFP/+ mice. PANX1+/+ and global PANX1−/− mice59 were provided by Dr. Brant Isakson. ALDH1L1GFP/+ mice26 were a gift from Dr. Manoj Patel at the University of Virginia.
For microglial depletion studies, mice were fed with chow containing a final dose of 660 mg/kg PLX3397, a CSF1R inhibitor widely used to eliminate microglia from the brain37. For microglial repopulation studies, the mice were switched from Plexxikon chow (formulated with Research Diets, New Jersey) back to control chow to allow for microglial repopulation50.
Acute and chronic window implantation
Mice were implanted with a chronic cranial window as previously described60. Briefly, during surgery, mice were anesthetized with isoflurane (5% for induction; 1–2% for maintenance) and placed on a heating pad. Using a dental drill, a circular craniotomy of >3 mm diameter was drilled at 2 mm posterior and 1.5 mm lateral to bregma; the craniotomy center was around the limb/trunk region of the somatosensory cortex. A 70% ethanol-sterilized 3 mm glass coverslip was placed inside the craniotomy. A light-curing dental cement (Tetric EvoFlow) was applied and cured with a Kerr Demi Ultra LED Curing Light (DentalHealth Products). iBond Total Etch glue (Heraeus) was applied to the rest of the skull, except for the region with the window. This was also cured with the LED Curing Light. The light-curing dental glue was used to attach a custom-made head bar onto the other side of the skull from which the craniotomy was performed. For acute imaging, imaging windows were monitored immediately after the surgery. For chronic imaging, mice were allowed to recover from anesthesia for 10 min on a heating pad before returning to their home cage. Mice were allowed to recover from the cranial window surgery for 2–4 weeks before the commencement of chronic imaging. Only surviving mice with a clear glass window were used for the imaging studies.
In vivo two-photon imaging
For acute or chronic imaging, mice were anesthetized with isoflurane (5% for induction; 1–2% for maintenance). The head of the anesthetized mice was stabilized and mounted by the head plate and the animal was placed on a heating plate at ~35 °C under the two-photon microscope. One hundred microliters of Rhodamine B dye (2 mg/mL) was injected intraperitoneally or subcutaneously to label the vasculature. For longitudinal imaging, the blood vessel architecture visible through the craniotomy window was carefully recorded as a precise map of the brain region being visualized and was used to trace back to the original imaging site for chronic imaging studies60. Imaging was conducted using a Leica SP8 Multiphoton microscope with a coherent laser. A wavelength of 880 nm was optimal for imaging both microglia and the blood vessel dye. The power output at the brain was maintained at 25 mW or below. Images were collected at a 1024 × 1024 pixel resolution using a 25 × 0.9 NA objective with a 1.5× optical zoom. Several fields of view of z-stack images were collected every 1–2 μm through a volume of tissue and used for analysis. To observe microglial dynamics, z-stack time-lapse images were acquired every minute at 2 μm steps in depth. For laser injury, the laser’s power was adjusted to 250 mW for 1 s at 880 nm wavelength and ×48 magnification.
Imaging data analysis
Image analysis was done using ImageJ version 1.53k. CAMs were identified as GFP+ cells having their cell bodies in close physical contact with the vasculature through the two-photon or confocal z-stack. CAMs were identified as ramified myeloid cells with cell bodies florescence overlapping with the capillary fluorescence through the z-stack of the image. To quantify CAMs, total microglia and CAMs were identified in a given stack of images and used to calculate the %CAM in the given field of view. Multiple (3–5) fields of view were used from each animal and the data averaged per animal to ensure a better sampling of the CAM population in a given animal. The dynamics of microglial movement was also analyzed for images collected from different fields of view imaged every week for 4 weeks. For each animal, 3–5 fields of view were chosen based on the clarity and alignment of the imaging over a volume of 120 × 296 × 296 µm3. The data from the fields of view were averaged and presented per animal. All PCMs and CAMs in the images from the previous week were identified and numbered, and these images were superimposed over images from the following week for the same region being analyzed. Cell bodies were regarded as “stable” if their positions remained the same between the superimposed images. Movement from parenchyma to the vessel was defined as “hop on,” whereas the opposite was considered as “hop off.” CAM movement along the vessel wall was considered as “crawling.”
Tissue preparation
For confocal microscopy studies, mice were anesthetized with 5% isoflurane, and transcardially perfused with sodium phosphate buffer (PBS; 50 mM at pH 7.4), followed by 4% paraformaldehyde (PFA). For electron microscopy studies, mice were anesthetized with sodium pentobarbital (80 mg/kg, intraperitoneally) and perfused with 3.5% acrolein, followed by 4% PFA61. All perfusion solutions were chilled on ice prior to use. Using a vibratome (Leica VT100S), 50 µm thick sections of the brain were cut in chilled PBS. Slices were then stored in cryoprotectant (40% PBS, 30% ethylene glycol, and 30% glycerol) at −20 °C while further processing took place29. Brain sections containing the ventral hippocampus CA1 (Bregma −3.27 and −4.03 in the stereotaxic atlas), the frontal cortex (Bregma 2.93 and –2.57), and sensorimotor cortex (Bregma –2.5 and +2.0) were examined.
Immunostaining and lectin labeling
For immunohistochemical staining for light microscopy analysis, brain sections were washed in PBS, blocked with blocking buffer, and incubated overnight at 4 °C with primary antibody solution against IBA1 (1:800, Wako, # 019-19741), CD206 (1:300, BioLegend, # 141701), CD31 (1:150, Millipore, # MAB1398Z), CD13 (0.8 µg/mL, R&D Systems, # AF2335), AQP4 (1:400, Sigma, # AB3594), CSF1R (1:200, Abcam, # ab254357), and P2RY12 (1:300, AnaSpec, # AS-55043A). Sections were then washed thoroughly to remove excess antibodies and treated with fluorescently tagged secondary antibodies, washed, mounted on slides, and cover-slipped with DAPI mounting medium. The details of the different staining conditions are enclosed in Table 1.
To evaluate the vasculature, a retroorbital injection of DyLight 594-LEL (10 µL Vector Laboratories, # DL-1177) was performed. Briefly, mice were placed in an isoflurane induction chamber, and when fully under anesthesia, mice were placed in lateral recumbency with the eye to be injected facing up. The skin was retracted resulting in the protrusion of the eye. A needle was inserted into the medial canthus at about a 45° angle and 10 µL of the lectin was gently injected. Ten minutes after lectin injection, mice were perfused with ice-cold PBS, followed by 4% PFA. The tissue was subsequently fixed overnight in 4% PFA.
For electron microscopy studies for IBA1 immunolabelling, brain sections were washed in PBS, quenched, and incubated with IBA1 primary antibody (Wako, # 019-19741). Sections were then treated first with goat anti‐rabbit secondary antibody conjugated to biotin (Jackson ImmunoResearch, code # 111-066-046) and then with ABC Vectastain system (1:100 in Tris‐buffered saline; Vector Laboratories, # PK‐6100). To reveal the immunostaining, sections were developed with diaminobenzidine (0.05%) and hydrogen peroxide (0.015%).
Fluorescence and transmission electron microscopy
While fluorescently immunolabelled brain sections were imaged at the confocal microscope or the Keyence microscope, and image analysis was done using ImageJ, immunostained electron microscopy sections were postfixed flat in 1% osmium tetroxide and dehydrated in progressively higher concentrations of ethanol. The sections were treated with propylene oxide, impregnated with Durcupan resin (EMS) overnight at room temperature, and then mounted between ACLAR embedding films (EMS). After curing the sheets at 55 °C for 72 h, areas of interest were removed from the embedding films, re-embedded at the tip of resin blocks, and cut to a thickness of 65–80 nm with an ultramicrotome (Leica Ultracut UC7). The ultrathin sections were examined in an FEI Tecnai Spirit G2 transmission electron microscope at 80 kV on bare square mesh grids (EMS). Photographs of the ultrathin sections were taken with an ORCAHR digital camera (10 MP; Hamamatsu) at various magnifications ranging from 440 to 9300. Ultrastructural profiles of brain parenchymal elements were identified according to well‐established criteria. Microglia were identified based on previously described ultrastructural characteristics as well as their immunoreactivity for IBA129,61.
RNAscope assay and fluorescence intensity determination
DyLight 594-Lectin (Vector Laboratories) was retro-orbitally injected into mice. Mice were freshly perfused, brain excised, and fixed in 4% PFA for 24 h at 4°C. One day later, the brain was immersed in 30% sucrose. The tissue was frozen in the optimal cutting temperature embedding media with dry ice. The blocks were sectioned by cutting 15 μm sections. Sall1 RNA probes were purchased from Advanced Cell Diagnostics (ACD). Here, we used probes against mouse Sall1 (ACD catalog # 469661-C3), positive control probe (ACD catalog # 310771), and negative probe (ACD catalog # 310043), and then performed the assay by using the RNAscope Fluorescent Multiplex Reagent Kit (ACD catalog # 320850) according to the manufacturer’s instructions. Briefly, the fixed frozen tissue slides were postfixed by immersing them in prechilled 4% PFA in 1× PBS for 15 min at 4 °C. We then dehydrated the tissues in 50% EtOH, 70% EtOH, and 100% EtOH each for 5 min at room temperature. Freshly prepared 1× Target Retrieval reagent (ACD catalog # 322000) in a beaker was made and maintained at uniform boiling at 99–100 °C. The slides were then kept in the solution for 3 min. Four drops of Protease III (ACD catalog # 322340) were added to each section, incubated for 30 min at 40 °C, before a hybridization assay was run. Sall1 fluorescence intensity was quantified for ten images captured with a ×40 objective lens for each (P2RY12+/+; CX3CR1GFP/+) mouse. CAMs and PCMs in the cortex were imaged in coronal sections by confocal microscopy with a thickness of 10 µm using an SP8 Lecia system. Analyses of fluorescence intensity were performed using ImageJ version 1.53k.
Blood vessel diameter analysis
Two-photon images were collected using the Leica SP8 Multi-photon microscope with the Leica Application Suite X version 3.5.7.23225 software. Confocal images were collected with a Leica TCS SP8 confocal microscope using the Leica Application Suite X version 3.5.5.19976 software. For blood vessel diameter analysis, two-photon images were collected of microglia and capillaries every other day (days 0, 2, and 4) from either control or PLX3397-treated mice. From collected images, capillaries were selected at random, and their lengths were measured in both conditions on the first (day 0) and fifth day (day 4) of control or PLX3397 treatment. The percent change in the capillary size was determined as a ratio of the capillary size by the fifth day compared to the first day of control or PLX3397 treatment. At least five capillaries from three to five fields of view (11 fields of view from 3 control and 13 fields of view from 3 PLX3397-treated mice) were quantified.
Morphological comparisons between CAMs and PCMs
For primary process analysis, the number of primary processes were randomly selected from a stack of images for either CAMs or PCMs and manually counted. At least 50 cells were counted from each animal from several fields of view and averaged. For cell body size analysis, the area around the cell body was drawn in ImageJ for CAM or PCM cells and the area was determined and averaged for at least 50 cells per animal. Individual CAMs and PCMs were identified and using ImageJ, the image was binarized and thresholded for each individual cell. The whole-cell area was quantified and averaged from at least 20 cells per animal. For basal motility, analysis was conducted as previously described62. Briefly, as with the whole-cell area, images were binarized through the time-lapse period of 15 min and changes between adjacent time frames were quantified and averaged for the 15 min period. For chemotactic responses, the number of processes that individual CAM and PCM cells showed in response to a laser-induced injury was quantified from four to five responding cells. For responding cells analysis, all cells that responded to the laser-induced injury within a 50 µm radius from the injury were quantified for CAMs and PCMs.
Blood vessel volume analysis
A thresholding segmentation was used to segment blood vessels from the surrounding tissue. Using the built-in surface rendering function in IMARIS, the vascular architecture of the tissue was 3D reconstructed, and the percent volume of the vasculature within the tissue volume was calculated by the software. To calculate the length of the vasculature in the given volume, the “skeletonization with filament object tracing” algorithm in IMARIS was used to mark the centerlines of the vessel network. The algorithm then calculated the vessel length based on the path length of the filamentous centerline depicting the vasculature.
KA seizures
Chemoconvulsive seizures were induced in mice using intraperitoneal injections of KA at 24–27 mg/kg body weight. Control mice were injected with an equal volume of saline that was used as the vehicle to dissolve the KA. Seizures were scored using a modified Racine scale as follows: (1) freezing behavior; (2) rigid posture with raised tail; (3) continuous head bobbing and forepaws shaking; (4) rearing, falling, and jumping; (5) continuous occurrence of level 4; and (6) loss of posture and generalized convulsion activity63,64. Only mice that progressed to stage 4/5 were used for seizure experiments.
Laser speckle contrast imaging
For laser speckle imaging, the skin on top of the skull was opened to expose the underlying skull and CBF imaging using the MoorFLPI-2 imaging system (Moor Instruments) was conducted to observe cerebral blood flow changes. During the experiment, CBF was measured in both brain hemispheres (minimum area size for CBF quantification: 3 × 3 mm2) for at least 5 mins. CBF is visualized using 16-color bands of perfusion units, and the absolute CBF perfusion units averaged across both hemispheres for mice were measured and used to compare baseline CBF. Mice were also monitored for their CBF in induced hyperemia (CO2 challenge) conditions following baseline CBF recordings for 5 min, after which normal conditions were restored65. For calculating the change in CBF, the difference between the mean CBF during hyperemia and the average CBF at baseline was normalized to the CBF at baseline, expressed as % change.
Statistical analysis
Student’s t test was used to compare two groups. Other comparisons were evaluated using one-way analysis of variance (more than two groups), followed by post hoc Tukey’s test for multiple comparisons within tested groups.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Supplementary information
Acknowledgements
We thank members of the Eyo lab and the Center for Brain Immunology and Glia (BIG) for valuable discussions in the development of this project. Graphical illustrations in Figs. 3k and 8 were made using BioRender (https://biorender.com/). This work was supported by The National Institutes of Health (R21NS119727 and R01NS122782; awarded to U.B.E.; 5R01HL137112 and 5P01HL120840 awarded to B.E.I.) and The Owens Family Foundation (awarded to U.B.E.). B.C. and W.A.M. III were supported by the National Institutes of Health Basic Cardiovascular Research Training Grant (5T32HL007284).
Source data
Author contributions
K.B., K.A.O. and K.S. contributed equally to the study by performing experiments and analysis. D.H.L., W.A.M. III, Y.-Y.S. and H.-R.C. also contributed some experiments and analysis to the project. J.O.U., S.A., Z.C., A.B.C.-S., B.C., L.J., J.B. and B.F. contributed analysis to the project. M.-E.T., K.B. and K.S. provided EM analysis. B.E.I., C.-Y.K. and U.B.E. contributed equipment and resources for the study. W.A.M. III, M.-E.T., B.E.I., C.-Y.K. and U.B.E. contributed reagents and resources for the project. K.B., K.A.O., K.S., D.H.L., H.-R.C., W.A.M. III, M.-E.T., B.E.I., C.-Y.K. and U.B.E. contributed to the writing and editing of the manuscript. U.B.E. oversaw the project.
Data availability
The datasets generated and analyzed in this study are available from the corresponding author upon reasonable request. Source data are provided with this paper.
Competing interests
The authors declare no competing interests.
Footnotes
Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors contributed equally: Kanchan Bisht, Kenneth A. Okojie, Kaushik Sharma.
Supplementary information
The online version contains supplementary material available at 10.1038/s41467-021-25590-8.
References
- 1.Magistretti PJ, Allaman I. A cellular perspective on brain energy metabolism and functional imaging. Neuron. 2015;86:883–901. doi: 10.1016/j.neuron.2015.03.035. [DOI] [PubMed] [Google Scholar]
- 2.Belanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-neuron metabolic cooperation. Cell Metab. 2011;14:724–738. doi: 10.1016/j.cmet.2011.08.016. [DOI] [PubMed] [Google Scholar]
- 3.Aldana BI. Microglia-specific metabolic changes in neurodegeneration. J. Mol. Biol. 2019;431:1830–1842. doi: 10.1016/j.jmb.2019.03.006. [DOI] [PubMed] [Google Scholar]
- 4.Blanchette M, Daneman R. Formation and maintenance of the BBB. Mech. Dev. 2015;138:8–16. doi: 10.1016/j.mod.2015.07.007. [DOI] [PubMed] [Google Scholar]
- 5.Keaney J, Campbell M. The dynamic blood-brain barrier. FEBS J. 2015;282:4067–4079. doi: 10.1111/febs.13412. [DOI] [PubMed] [Google Scholar]
- 6.Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 2013;19:1584–1596. doi: 10.1038/nm.3407. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and dysfunction of the blood-brain barrier. Cell. 2015;163:1064–1078. doi: 10.1016/j.cell.2015.10.067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron. 2017;96:17–42. doi: 10.1016/j.neuron.2017.07.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Quelhas P, Baltazar G, Cairrao E. The neurovascular unit: focus on the regulation of arterial smooth muscle cells. Curr. Neurovasc. Res. 2019;16:502–515. doi: 10.2174/1567202616666191026122642. [DOI] [PubMed] [Google Scholar]
- 10.Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell. 2014;158:15–24. doi: 10.1016/j.cell.2014.06.008. [DOI] [PubMed] [Google Scholar]
- 11.Schafer DP, Stevens B. Microglia function in central nervous system development and plasticity. Cold Spring Harb. Perspect. Biol. 2015;7:a020545. doi: 10.1101/cshperspect.a020545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Nayak D, Roth TL, McGavern DB. Microglia development and function. Annu. Rev. Immunol. 2014;32:367–402. doi: 10.1146/annurev-immunol-032713-120240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Stevens B, Schafer DP. Roles of microglia in nervous system development, plasticity, and disease. Dev. Neurobiol. 2018;78:559–560. doi: 10.1002/dneu.22594. [DOI] [PubMed] [Google Scholar]
- 14.Sierra A, Paolicelli RC, Kettenmann H. Cien anos de microglia: milestones in a century of microglial research. Trends Neurosci. 2019;42:778–792. doi: 10.1016/j.tins.2019.09.004. [DOI] [PubMed] [Google Scholar]
- 15.Fantin A, et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood. 2010;116:829–840. doi: 10.1182/blood-2009-12-257832. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Rymo SF, et al. A two-way communication between microglial cells and angiogenic sprouts regulates angiogenesis in aortic ring cultures. PLoS ONE. 2011;6:e15846. doi: 10.1371/journal.pone.0015846. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Checchin D, Sennlaub F, Levavasseur E, Leduc M, Chemtob S. Potential role of microglia in retinal blood vessel formation. Invest. Ophthalmol. Vis. Sci. 2006;47:3595–3602. doi: 10.1167/iovs.05-1522. [DOI] [PubMed] [Google Scholar]
- 18.Zhao X, Eyo UB, Murugan M, Wu LJ. Microglial interactions with the neurovascular system in physiology and pathology. Dev. Neurobiol. 2018;78:604–617. doi: 10.1002/dneu.22576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Spangenberg E, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model. Nat. Commun. 2019;10:3758. doi: 10.1038/s41467-019-11674-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Bowyer JF, et al. Microglial activation and responses to vasculature that result from an acute LPS exposure. Neurotoxicology. 2020;77:181–192. doi: 10.1016/j.neuro.2020.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Haruwaka K, et al. Dual microglia effects on blood brain barrier permeability induced by systemic inflammation. Nat. Commun. 2019;10:5816. doi: 10.1038/s41467-019-13812-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Lou N, et al. Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier. Proc. Natl Acad. Sci. USA. 2016;113:1074–1079. doi: 10.1073/pnas.1520398113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Joost E, et al. Microglia contribute to the glia limitans around arteries, capillaries and veins under physiological conditions, in a model of neuroinflammation and in human brain tissue. Brain Struct. Funct. 2019;224:1301–1314. doi: 10.1007/s00429-019-01834-8. [DOI] [PubMed] [Google Scholar]
- 24.Mondo E, et al. A developmental analysis of juxtavascular microglia dynamics and interactions with the vasculature. J. Neurosci. 2020;40:6503–6521. doi: 10.1523/JNEUROSCI.3006-19.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Huang, L., Nakamura, Y., Lo, E. H. & Hayakawa, K. Astrocyte signaling in the neurovascular unit after central nervous system injury. Int. J. Mol. Sci. 20, 10.3390/ijms20020282 (2019). [DOI] [PMC free article] [PubMed]
- 26.Yang Y, et al. Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in vivo in astroglial reporter mice. Glia. 2011;59:200–207. doi: 10.1002/glia.21089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Bell RD, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68:409–427. doi: 10.1016/j.neuron.2010.09.043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Goldmann T, et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol. 2016;17:797–805. doi: 10.1038/ni.3423. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Bisht K, et al. Dark microglia: a new phenotype predominantly associated with pathological states. Glia. 2016;64:826–839. doi: 10.1002/glia.22966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Cronk JC, et al. Peripherally derived macrophages can engraft the brain independent of irradiation and maintain an identity distinct from microglia. J. Exp. Med. 2018;215:1627–1647. doi: 10.1084/jem.20180247. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Zhang Y, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014;34:11929–11947. doi: 10.1523/JNEUROSCI.1860-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Hickman SE, et al. The microglial sensome revealed by direct RNA sequencing. Nat. Neurosci. 2013;16:1896–1905. doi: 10.1038/nn.3554. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Buttgereit A, et al. Sall1 is a transcriptional regulator defining microglia identity and function. Nat. Immunol. 2016;17:1397–1406. doi: 10.1038/ni.3585. [DOI] [PubMed] [Google Scholar]
- 34.Eyo UB, et al. P2Y12R-dependent translocation mechanisms gate the changing microglial landscape. Cell Rep. 2018;23:959–966. doi: 10.1016/j.celrep.2018.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Haynes SE, et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci. 2006;9:1512–1519. doi: 10.1038/nn1805. [DOI] [PubMed] [Google Scholar]
- 36.MacVicar BA, Thompson RJ. Non-junction functions of pannexin-1 channels. Trends Neurosci. 2010;33:93–102. doi: 10.1016/j.tins.2009.11.007. [DOI] [PubMed] [Google Scholar]
- 37.Elmore MR, et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380–397. doi: 10.1016/j.neuron.2014.02.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.De Schepper, S., Crowley, G. & Hong, S. Understanding microglial diversity and implications for neuronal function in health and disease. Dev. Neurobiol.10.1002/dneu.22777 (2020). [DOI] [PMC free article] [PubMed]
- 39.Masuda T, Sankowski R, Staszewski O, Prinz M. Microglia heterogeneity in the single-cell era. Cell Rep. 2020;30:1271–1281. doi: 10.1016/j.celrep.2020.01.010. [DOI] [PubMed] [Google Scholar]
- 40.Geirsdottir L, et al. Cross-species single-cell analysis reveals divergence of the primate microglia program. Cell. 2020;181:746. doi: 10.1016/j.cell.2020.04.002. [DOI] [PubMed] [Google Scholar]
- 41.Young AMH, et al. A map of transcriptional heterogeneity and regulatory variation in human microglia. Nat. Genet. 2021;53:861–868. doi: 10.1038/s41588-021-00875-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Bosco DB, et al. RNAseq analysis of hippocampal microglia after kainic acid-induced seizures. Mol. Brain. 2018;11:34. doi: 10.1186/s13041-018-0376-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Rajan WD, et al. Dissecting functional phenotypes of microglia and macrophages in the rat brain after transient cerebral ischemia. Glia. 2019;67:232–245. doi: 10.1002/glia.23536. [DOI] [PubMed] [Google Scholar]
- 44.Li Q, et al. Developmental heterogeneity of microglia and brain myeloid cells revealed by deep single-cell RNA sequencing. Neuron. 2019;101:207–223.e210. doi: 10.1016/j.neuron.2018.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Keren-Shaul H, et al. A unique microglia type associated with restricting development of alzheimer’s disease. Cell. 2017;169:1276–1290.e1217. doi: 10.1016/j.cell.2017.05.018. [DOI] [PubMed] [Google Scholar]
- 46.Baalman K, et al. Axon initial segment-associated microglia. J. Neurosci. 2015;35:2283–2292. doi: 10.1523/JNEUROSCI.3751-14.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Grossmann R, et al. Juxtavascular microglia migrate along brain microvessels following activation during early postnatal development. Glia. 2002;37:229–240. doi: 10.1002/glia.10031. [DOI] [PubMed] [Google Scholar]
- 48.Davalos D, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005;8:752–758. doi: 10.1038/nn1472. [DOI] [PubMed] [Google Scholar]
- 49.Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314–1318. doi: 10.1126/science.1110647. [DOI] [PubMed] [Google Scholar]
- 50.Huang Y, et al. Repopulated microglia are solely derived from the proliferation of residual microglia after acute depletion. Nat. Neurosci. 2018;21:530–540. doi: 10.1038/s41593-018-0090-8. [DOI] [PubMed] [Google Scholar]
- 51.Kana V, et al. CSF-1 controls cerebellar microglia and is required for motor function and social interaction. J. Exp. Med. 2019;216:2265–2281. doi: 10.1084/jem.20182037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Eyo UB, et al. Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J. Neurosci. 2014;34:10528–10540. doi: 10.1523/JNEUROSCI.0416-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Dissing-Olesen L, et al. Activation of neuronal NMDA receptors triggers transient ATP-mediated microglial process outgrowth. J. Neurosci. 2014;34:10511–10527. doi: 10.1523/JNEUROSCI.0405-14.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Sharma AK, et al. Pannexin-1 channels on endothelial cells mediate vascular inflammation during lung ischemia-reperfusion injury. Am. J. Physiol. Lung Cell Mol. Physiol. 2018;315:L301–L312. doi: 10.1152/ajplung.00004.2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Good ME, et al. Emerging concepts regarding pannexin 1 in the vasculature. Biochem. Soc. Trans. 2015;43:495–501. doi: 10.1042/BST20150045. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Lohman AW, et al. Pannexin 1 channels regulate leukocyte emigration through the venous endothelium during acute inflammation. Nat. Commun. 2015;6:7965. doi: 10.1038/ncomms8965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Jung S, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol. Cell. Biol. 2000;20:4106–4114. doi: 10.1128/MCB.20.11.4106-4114.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Andre P, et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J. Clin. Invest. 2003;112:398–406. doi: 10.1172/JCI17864. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Poon IK, et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature. 2014;507:329–334. doi: 10.1038/nature13147. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Bisht, K., Sharma, K. & Eyo, U. B. Precise brain mapping to perform repetitive in vivo imaging of neuro-immune dynamics in mice. J. Vis. Exp.10.3791/61454 (2020). [DOI] [PubMed]
- 61.Tremblay ME, Lowery RL, Majewska AK. Microglial interactions with synapses are modulated by visual experience. PLoS Biol. 2010;8:e1000527. doi: 10.1371/journal.pbio.1000527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Eyo U, Dailey ME. Effects of oxygen-glucose deprivation on microglial mobility and viability in developing mouse hippocampal tissues. Glia. 2012;60:1747–1760. doi: 10.1002/glia.22394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Avignone E, Ulmann L, Levavasseur F, Rassendren F, Audinat E. Status epilepticus induces a particular microglial activation state characterized by enhanced purinergic signaling. J. Neurosci. 2008;28:9133–9144. doi: 10.1523/JNEUROSCI.1820-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972;32:281–294. doi: 10.1016/0013-4694(72)90177-0. [DOI] [PubMed] [Google Scholar]
- 65.Kazmi SM, Richards LM, Schrandt CJ, Davis MA, Dunn AK. Expanding applications, accuracy, and interpretation of laser speckle contrast imaging of cerebral blood flow. J. Cereb. Blood Flow Metab. 2015;35:1076–1084. doi: 10.1038/jcbfm.2015.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets generated and analyzed in this study are available from the corresponding author upon reasonable request. Source data are provided with this paper.